Neuro Therapia

What Neuro Therapia does

NeuroTherapia is a clinical-stage biotechnology company founded in 2015 as a spin-out from Cleveland Clinic by physician-scientists Drs. Mohamed Naguib and Joseph Foss. The company is developing oral small-molecule therapeutics that target microglia-mediated neuroinflammation as the underlying driver of central nervous system (CNS) diseases, with an initial focus on Alzheimer's disease (AD) and additional pipeline programs in Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and chronic pain. Its lead asset, NTRX-07, is a first-in-class, highly selective cannabinoid type 2 (CB2) receptor agonist designed to shift microglia from a pro-inflammatory M1 phenotype to a neuroprotective M2 phenotype, reducing neuronal damage and amyloid beta accumulation while avoiding the psychoactive effects associated with cannabinoid compounds. By targeting neuroinflammation rather than direct protein (amyloid/tau) removal, NTRX-07 is positioned as a potential combination partner with approved antibody therapies.

NeuroTherapia has advanced NTRX-07 through Phase 1a (single ascending dose in healthy volunteers, completed December 2020), Phase 1b (in AD patients, completed 2023 with favorable safety and trend toward cognitive improvement on ADAS-Cog and qEEG), and Phase 2a (48-patient randomized trial across sites in Hungary, Poland, and the Czech Republic, completed April 2026). The Phase 2a study met its core safety and PK objectives and produced directionally supportive signals across NF-Light, IL-8, Aβ42, and Aβ42/40 biomarkers, MRI stabilization trends, and qEEG. The company is currently conducting deeper MRI analysis in collaboration with Oxford Brain Diagnostics using its CDM Explore platform. The next regulatory milestone is a follow-on Phase 2 study, anticipated with CRU Global as CRO.

The business model is pre-revenue drug development with a planned future monetization via out-licensing, co-development partnerships, or co-promotion with a major pharmaceutical company upon regulatory approval. To date, the company has funded operations through approximately $22.1M in equity (a $1M Cleveland Clinic pre-seed in 2015, an $8.8M Series A led by Brain Trust Accelerator Fund II in September 2020, and a $12.3M Series B first close led by Cleveland Clinic Foundation in August 2024), plus non-dilutive grants from the Alzheimer's Drug Discovery Foundation ($1.7M in 2016), the Alzheimer's Association Part the Cloud program (multiple grants 2019–2024), and Ohio Third Frontier ($150K in 2020). The company operates with a 1–10 person team from Gates Mills, Ohio, with clinical operations extending to Central Europe.

Name

Neuro Therapia

Legal name

NeuroTherapia, Inc.

Website

https://neurotherapia.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroTherapia is a clinical-stage biotech developing NTRX-07, an oral small-molecule CB2 receptor agonist that targets microglia-mediated neuroinflammation to treat Alzheimer's disease and other CNS disorders. Founded in 2015 as a Cleveland Clinic spin-out, the company completed Phase 2a in April 2026 and is pre-revenue.

Ownership category

akta.pro rank

Product category

CNS Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• CB2 receptor agonists
• Neuroinflammation therapeutics
• Alzheimer's disease drugs
• CNS drug development
• Microglia-targeted therapy

Headquarters

HQ city

Ohio

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-revenue clinical-stage biotechnology company developing NTRX-07 for Alzheimer's disease and other neuroinflammatory conditions. Revenue will be generated through drug licensing, co-development partnerships, and eventual product sales upon regulatory approval.

Distribution channels1 record

Marketing channels4 records

Core offering

NeuroTherapia is a clinical-stage biotechnology company developing NTRX-07, an orally available small molecule cannabinoid type 2 (CB2) receptor agonist that targets microglia-mediated neuroinflammation in the central nervous system. The lead program is being developed initially for Alzheimer's disease, with planned expansion into Parkinson's disease, ALS, multiple sclerosis, and chronic pain syndromes. The company has completed Phase 1a, Phase 1b, and Phase 2a clinical trials demonstrating favorable safety and biological activity signals.

Product overview

NeuroTherapia is a clinical-stage biotechnology company developing oral, small-molecule drugs to address neuroinflammatory conditions of the central nervous system (CNS). The company's primary product is NTRX-07, a CB2 receptor agonist being developed for the treatment of Alzheimer's disease. The company has completed Phase 1a, Phase 1b, and Phase 2a clinical trials demonstrating favorable safety profiles and promising signals across safety, PK, biomarkers, MRI, EEG, and clinical outcomes. NTRX-07 works by inhibiting microglia cells to reduce neuroinflammation without affecting the clearance of toxic beta amyloid, offering potential for combination therapy with approved antibody treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• NTRX-07 An orally available small molecule and highly selective cannabinoid type 2 (CB2) receptor agonist that activates microglia CB2 receptors, promoting transition from pro-inflammatory M1 to neuroprotective M2 phenotype, reducing neuroinflammation, decreasing amyloid beta levels, and improving synaptic plasticity, learning, and memory. Being developed for Alzheimer's disease and other neuroinflammatory CNS conditions.

Quantifiable outcome

• Phase 2a: NTRX-07 was safe and well tolerated with no active-arm serious TEAE signal; PK profile consistent with preclinical exposure targets; favorable trends on NF-Light, IL8, AB42, and AB42/AB40 ratio biomarkers; MRI findings trending toward stabilization on active treatment.
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered strategic.

• Oxford Brain Diagnostics LtdstrategicTechnology or IntegrationCollaboration established following Phase 2a trial completion in April 2026. NeuroTherapia is working with Oxford Brain Diagnostics to conduct more thorough analysis of MRI data using its CDM Explore platform, comparing MRI results with changes in neuroinflammatory biomarkers, qEEG, and cognitive test results.
• CRU GlobalstrategicImplementation/ SI/ Consulting PartnerCRU Global, a leading European CRO, managed the Phase 2a clinical trial conducted at sites in Hungary, Poland, and the Czech Republic. Peter Kovacs, President of CRU Global, noted interest in continuing to work with NeuroTherapia on the next Phase 2 study. CRU Global is also an investor in the Series B round.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cognition Therapeutics: Clinical-stage biotech developing oral small molecules (e.g., CT1812) for Alzheimer's disease and other neurodegenerative conditions. Co-founded by NeuroTherapia CEO Tony Giordano, making it one of the closest comparables in mechanism, indication, stage, and management DNA.
• Anavex Life Sciences: Clinical-stage biotech developing ANAVEX 2-73 (blarcamesine), a small-molecule sigma-1 receptor agonist for Alzheimer's disease and other CNS indications. Highly comparable as a small-cap CNS-focused company with an oral small-molecule AD asset in mid-stage trials.
• INmune Bio: Clinical-stage biotech developing XPro1595, a dominant-negative TNF inhibitor that targets neuroinflammation in Alzheimer's disease. Closely comparable mechanism (neuroinflammation in AD) and stage (Phase 2) to NeuroTherapia's NTRX-07.
• Athira Pharma: Clinical-stage biotech developing small-molecule HGF/MET pathway modulators (e.g., fosgonimeton) for Alzheimer's disease and other neurodegenerative disorders. Comparable as an oral small-molecule AD-focused biotech at similar clinical stage.
• Alector: Clinical-stage biotech developing immuno-neurology therapeutics that target microglia and other immune cells in neurodegeneration (e.g., AL002 for Alzheimer's). Strongly comparable in microglia-focused AD approach, though larger and partnered with GSK.
• Cortexyme (now Lighthouse Pharma): Clinical-stage biotech developing COR388 (atuzaginstat), an oral small-molecule targeting gingipain for Alzheimer's disease. Comparable as an oral small-molecule mid-stage AD biotech that has experienced clinical setbacks.
• Prothena: Clinical-stage biotech developing protein-misfolding therapeutics for neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. Comparable focus on disease-modifying CNS therapies, though Prothena is more established with multiple clinical assets and a Bristol-Myers Squibb partnership.
• AC Immune: Clinical-stage Swiss biotech developing therapeutics and diagnostics targeting misfolded proteins and neuroinflammation in Alzheimer's and Parkinson's disease. Comparable AD-focused pipeline with multiple programs in mid-stage trials and pharma partnerships (e.g., Roche/Genentech).

Broad incumbents

• Denali Therapeutics: Larger clinical-stage biotech developing a broad portfolio of small molecules and biologics for neurodegenerative diseases, including lysosomal and neuroinflammation programs. Comparable CNS focus but operates at much greater scale with multiple programs and pharma partnerships.
• Biogen: Major CNS-focused biopharmaceutical company commercializing Leqembi (lecanemab) for Alzheimer's disease, the leading anti-amyloid antibody therapy. Highly relevant as the dominant AD player and the most likely strategic partner or acquirer of a neuroinflammation-focused asset like NTRX-07.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neurotherapia

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuro Therapia